These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 314328)

  • 1. Serum levels of methotrexate by the ligand-binding assay after "high-dose" therapy for osteosarcoma.
    Roberts D; Kidd W; Pratt CB; Peck C; Grinnel J
    Cancer; 1979 Sep; 44(3):881-90. PubMed ID: 314328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
    Allen J; Rosen G; Juergens H; Mehta B
    J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
    Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevention of methotrexate toxicity by thymidine infusions in humans.
    Ensminger WD; Frei E
    Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
    Erttmann R; Bielack S; Landbeck G
    Cancer Chemother Pharmacol; 1985; 15(2):101-4. PubMed ID: 3874719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.
    Wang YM; Kim PY; Lantin E; van Eys DC; Romsdahl MM; Sutow WW
    Med Pediatr Oncol; 1978; 4(3):221-9. PubMed ID: 308151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose leucovorin as sole therapy for methotrexate toxicity.
    Flombaum CD; Meyers PA
    J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate.
    Jaffe N; Prudich J; Knapp J; Wang YM; Bowman R; Cangir A; Ayala A; Chuang V; Wallace S
    J Clin Oncol; 1983 Jul; 1(7):428-31. PubMed ID: 6607977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.
    Erttmann R; Bielack S; Landbeck G
    J Cancer Res Clin Oncol; 1985; 109(1):86-8. PubMed ID: 3855853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.